ICM
EBS icon

Islay Capital Management’s Emergent Biosolutions EBS Stock Holding History

Islay Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,942
Closed -$91K – 260
2022
Q2 		$91K Buy
+2,942
New +$100K 0.09% 147
2021
Q3 		– Sell
-1,397
Closed -$88K – 291
2021
Q2 		$88K Buy
+1,397
New +$89.7K 0.07% 173

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Islay Capital Management's EBS Position: Q3 2022 in Review

Islay Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 2,942 shares — an estimated $91K sold.

Islay Capital Management first reported a position in EBS in Q2 2021 and held it in 2 quarters. The position peaked at $91K in Q2 2022. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

  • Islay Capital Management reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
  • Islay Capital Management sold 2,942 Emergent Biosolutions shares in Q3 2022, an estimated $91K.
  • Islay Capital Management first reported a position in Emergent Biosolutions in Q2 2021 and held it in 2 quarters.
  • Islay Capital Management's Emergent Biosolutions position peaked at $91K in Q2 2022.
  • 211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on Islay Capital Management's 13F filing for Q3 2022, filed 21 Oct 2022.